Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-019-48045-z.pdf
Reference26 articles.
1. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25–34 (2009).
2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359(4), 378–90 (2008).
3. Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391(10126), 1163–1173 (2018).
4. Yamamoto, Y. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 6, 18 (2014).
5. Kudo, M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 7(1), 1–19 (2018).
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma;Journal of Gastroenterology;2024-04-07
2. A case of hepatic encephalopathy in a patient with unresectable hepatocellular carcinoma and portal vein tumor thrombus successfully treated with shunt embolization and multimodal therapy;Kanzo;2024-01-23
3. Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example;Journal of Oncology Pharmacy Practice;2024-01-22
4. Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study;Drug Design, Development and Therapy;2022-12
5. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma;BMC Cancer;2022-08-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3